Molgramostim

Summary

Molgramostim (CHEMBL2109134) is a phase-3 clinical-stage protein (ATC L03AA03); indicated across 8 conditions including neoplasm and acute myeloid leukemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• ATC class: L03AA03
• Indications: 8 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109134
Name	Molgramostim
Type	Protein
Max phase	3
ATC	L03AA03

Also known as: Leucomax, Molgradex, Molgramostim, Molgramostim (genetical recombination), Molgramostim rdna, SCH 39300, SCH-39300, MOLGRAMOSTIM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222
pulmonary alveolar proteinosis	3	MONDO:0001437	MONDO:0012579
severe acute respiratory syndrome	2	MONDO:0005091	EFO:0000694
cutaneous melanoma	2	MONDO:0005012	EFO:0000389
mycobacterial infectious disease	2	MONDO:0020590	EFO:0009429

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	2
PHASE4	1
PHASE2/PHASE3	1
PHASE1/PHASE2	1
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00464217	PHASE4	COMPLETED	Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years
NCT04544293	PHASE3	ACTIVE_NOT_RECRUITING	Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
NCT06431776	PHASE3	RECRUITING	Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
NCT01729663	PHASE2/PHASE3	UNKNOWN	Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients
NCT03482752	PHASE3	TERMINATED	Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
NCT02702180	PHASE2	COMPLETED	Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis
NCT03421743	PHASE2	COMPLETED	Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection
NCT05501340	PHASE1/PHASE2	UNKNOWN	PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites
NCT02468908	PHASE1	COMPLETED	Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects
NCT07341360	EARLY_PHASE1	RECRUITING	Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).